Hasil Pencarian - Subash C. Jonnalagadda

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

    Past, Present, and a Glance into the Future of Multiple Myeloma Treatment oleh Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma

    Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma oleh Omar S. Al-Odat, Daniel A. Guirguis, Nicole K. Schmalbach, Gabriella Yao, Tulin Budak-Alpdogan, Subash C. Jonnalagadda, Manoj K. Pandey

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells

    Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells oleh Kuntal Bhowmick, Max von Suskil, Omar S. Al-Odat, Weam Othman Elbezanti, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

    KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis oleh Omar S. Al-Odat, Omar S. Al-Odat, Weam Othman Elbezanti, Weam Othman Elbezanti, Krishne Gowda, Sandeep K. Srivastava, Shantu G. Amin, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey

    Diterbitkan 2024-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma

    Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma oleh Max Von Suskil, Kazi Nasrin Sultana, Weam Othman Elbezanti, Omar S. Al-Odat, Robert Chitren, Amit K. Tiwari, Kishore B. Challagundla, Sandeep Kumar Srivastava, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

    Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma oleh Omar S. Al-Odat, Omar S. Al-Odat, Max von Suskil, Max von Suskil, Robert J. Chitren, Robert J. Chitren, Weam O. Elbezanti, Weam O. Elbezanti, Sandeep K. Srivastava, Tulin Budak-Alpddogan, Subash C. Jonnalagadda, Bharat B. Aggarwal, Manoj Pandey

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

    Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cell... oleh Weam Othman Elbezanti, Weam Othman Elbezanti, Omar S. Al-Odat, Omar S. Al-Odat, Robert Chitren, Robert Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: